Mucus plugging is a challenge in asthma care. It’s thick, sticky mucus that blocks the airways and doesn’t respond to regular inhalers. Even when inflammation improves, these plugs can lower lung function, limit how well medicine works, and make asthma harder to control. In this episode, we break down the study: “Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma,” published October 28, 2025. The analysis looks at whether dupilumab (Dupixent), a biologic that blocks IL-4 and IL-13, can lower mucus burden and improve lung function, especially in people who start with a high “mucus plug score.” What we cover in our episode about dupilumab and mucus plugging Why mucus plugging matters in asthma: Discover how thick, sticky mucus can block airways, make it harder to breathe, and why standard inhalers and steroids don’t clear these plugs. How dupilumab may help: Learn how this biologic blocks IL-4 and IL-13, two key drivers of type 2 inflammation that increase mucus production and thickness. Inside the VESTIGE study: Hear how researchers measured mucus burden using CT scans and “mucus plug scores” to see if dupilumab could reduce plugging in moderate-to-severe asthma. What the results showed: Find out how dupilumab lowered mucus plug scores, reduced airway inflammation, and improved lung function (FEV₁), especially in people with high mucus burden. What this means for patients: Learn why identifying and treating mucus plugging may help improve breathing, reduce flare-ups, and make asthma easier to manage day to day. 📌INFOGRAPHIC to follow along  RESOURCES: What is asthma? What is type 2 inflammation? When Asthma Is More Than Just Asthma: Type 2 Inflammation More about dupilumab (Dupixent) The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference. ___ A special collaboration with the American Thoracic Society.  This podcast was made in partnership with Allergy & Asthma Network. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.    

Living with constant congestion, facial pressure, or a loss of smell can make daily life exhausting. For many people, these symptoms are more than just allergies or a lingering cold. They may be signs of chronic rhinosinusitis with nasal polyps (CRSwNP). Dr. Rohit Katial joins Kortney and Dr. G to unpack what CRSwNP really is, how it develops, and why type 2 inflammation plays such a key role. Together, they explain what’s happening inside the sinuses, what symptoms to look for, and when it’s time to see a specialist. What we cover about CRSwNP: What CRSwNP means: Chronic rhinosinusitis with nasal polyps is long-term inflammation of the nose and sinuses that lasts 12 weeks or more. What nasal polyps are: Soft, fluid-filled sacs (often “grape” or “pea” sized) that block airflow and lead to congestion and smell loss. Why it happens: Type 2 inflammation drives CRSwNP. Immune messengers like IL-4, IL-5, and IL-13 cause swelling and fluid buildup in the nasal lining. Who it affects: CRSwNP often overlaps with asthma, allergies, or aspirin sensitivity (AERD or Samter’s Triad), making symptoms worse. When to seek help: If congestion, pressure, or loss of smell lasts more than 12 weeks, see an allergist or an ENT specialist. Early care can prevent sinus damage and improve breathing and quality of life. More episodes to support CRSwNP Ep. 101: What is Type 2 Inflammation? Ep. 102: Comorbidities of Type 2 Inflammation -  Connecting the Dots Between Multiple Allergic Conditions Ep. 109: Tezepelumab & Nasal Polyps - Inside the WAYPOINT Phase III Trial ___ Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today’s episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Navigating food allergies is tough enough, but adding family dynamics to the mix can make things even more complicated. When loved ones don’t understand you or your child’s allergies or dismiss the rules meant to keep them safe, it can lead to conflict, hurt feelings, and stress for everyone involved. Kortney and Dr. Payel Gupta sit down with psychologist Dr. Amanda Whitehouse to talk about how families can find common ground when emotions run high. Together, they unpack what it means to stay regulated in difficult conversations, how to set healthy boundaries with family members, and why understanding different coping styles can help prevent conflict before it starts. What we cover about communication and boundary-setting for food allergy families: Coping styles and conflict: Learn how different stress responses, such as “fight” versus “flight,” shape how partners, parents, and relatives react to food allergy challenges. Staying calm and regulated: Understand how your body reacts to stress and how recognizing those signals can help you stay grounded during tough conversations. Setting and holding boundaries: Get practical tips for explaining what feels safe, keeping communication clear, and responding calmly when others push back. Working together as a team: Whether it’s with your partner, kids, or extended family, learn how to support each other and stay united when emotions rise. Bridging family differences: Explore ways to include children and siblings in allergy safety, and approach older relatives with patience and compassion when views or communication styles differ. ___ Made in partnership with The Allergy & Asthma Network. Thanks to Genentech for sponsoring today’s episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

For decades, allergists have focused on blocking what happens outside the mast cell: histamine, IgE, and interleukins. But now, there’s a new way to stop allergic inflammation before it even starts: by targeting what happens inside the cell with BTK Inhibitors. Dr. Payel Gupta and Kortney are joined by Dr. Matthew Giannetti to unpack what BTK actually does and why inhibiting it represents an exciting breakthrough in allergy and immunology. Together, they explore how BTK inhibitors work, why this inside-the-cell approach is different from anything before, and what it could mean for people living with chronic spontaneous urticaria (CSU). What the episode covers about BTK inhibitors: BTK explained: Bruton’s tyrosine kinase is a pivotal “last step” before mast-cell degranulation. How BTK inhibitors work: Blocking BTK can stop histamine release downstream of many outside triggers. The science: Why BTK binding is irreversible for each molecule and how the body “re-makes” BTK over time. Safety in brief: A look at petechiae (small pinpoint spots), what to monitor, and how shared decision-making guides treatment choices. The future of BTK inhibitors: Exploring their potential role in other allergic conditions.    ____ Made in partnership with The Allergy & Asthma Network. Thanks to Novartis for sponsoring today’s episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Seeing your allergist on a screen instead of in the office might feel strange at first, but for many people with allergies, telehealth isn’t just convenient.  it’s effective. In this episode, we sit down with telemedicine pioneer Dr. Jay Portnoy to explore how virtual allergy care works, what it can and can’t do, and how it’s helping patients get the care they need without the wait or the long drive. Dr. Portnoy shares over two decades of experience leading allergy telemedicine programs in rural areas and explains how remote care has grown from a fringe idea into a standard part of allergy care. He and Dr. G also discuss the benefits for both patients and clinicians. So how do you know when telehealth is enough and when it’s not? What we cover in our episode about virtual allergy care and telemedicine: How does telemedicine work for allergy patients? Learn how video visits and asynchronous tools are making care faster and easier, especially in rural or underserved areas. Telemendine limitations. We break down when in-person care is still needed, like for food challenges, skin tests, or urgent symptoms. Privacy and safety in virtual care. From HIPAA-compliant platforms to quiet spaces at home or in schools, we talk about how to keep your virtual visit just as private as a clinic one. How testing works with telemedicine. Telehealth doesn’t mean skipping tests. Many can be ordered remotely and done at a local lab or clinic near you. The future of allergy care. Hear how virtual care is shifting toward patient choice, whether you want to video call, send a message, or still come in. ___ Made in partnership with The Allergy & Asthma Network. Thanks to Genentech for sponsoring today’s episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Multiple food allergies are a daily stressor for millions of families. From avoiding social events to fearing accidental exposures, it can feel like living in a constant state of alert. Until recently, there were no FDA-approved treatments that targeted more than one allergen at a time. In this episode, we break down the study: “Omalizumab for the Treatment of Multiple Food Allergies,” published in 2024 in the New England Journal of Medicine. Known as the OUtMATCH trial, it’s the first large-scale study to show that omalizumab (Xolair), a biologic already used for asthma and hives, may help people with multiple food allergies by raising the threshold for reactions. We explain how omalizumab works by blocking IgE, the antibody that triggers allergic reactions, and how the study measured changes in reaction thresholds (the amount of an allergen a person can ingest before reacting). We also explore the trial design, results, safety profile, and what all of this means for the day-to-day management of food allergies. What we cover in our episode about OUtMATCH trial How omalizumab works to prevent allergic reactions: Learn how blocking IgE increases the amount of allergen needed to trigger symptoms, offering protection from small, accidental exposures. Who qualified for the OUtMATCH trial and why: Find out which patients were included and how eligibility impacted outcomes. What success looked like in this study: Understand how researchers defined protection across multiple allergens. Why not everyone responded the same to omalizumab: Explore the variability in results and what it means for clinical care. What else the study found beyond food challenges: Hear about safety findings, quality of life data, and the open-label extension. 📌 INFOGRAPHIC to follow along  The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference. ___ Made in partnership with The Allergy & Asthma Network. Thanks to Genentech for sponsoring today’s episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.  

When people get hives or swelling, they often think it’s caused by an allergy. But in the case of chronic spontaneous urticaria (CSU), the culprit is often your own immune system. CSU isn’t your typical allergic reaction, instead, it’s frequently an autoimmune condition, where the immune system misfires and activates mast cells without any external trigger. In this episode, Dr. Payel Gupta and Kortney unpack what it means for CSU to be autoimmune and autoallergic. They explain how IgE and IgG antibodies can trigger histamine release, leading to hives and swelling. You’ll also learn why allergy testing isn’t useful for diagnosing CSU, and how tests like IgG food sensitivity panels can do more harm than good by leading to unnecessary food avoidance and confusion. What we cover in our episode about autoimmune CSU and chronic hives: Is CSU an allergy? Why CSU is often mistaken for an allergic reaction—and why standard allergy tests rarely provide helpful answers. How the immune system works in CSU: What mast cells are, how they release histamine, and their central role in chronic spontaneous urticaria. Understanding autoimmune CSU: Learn how the immune system can trigger hives from within, including the roles of IgE and IgG antibodies. Autoimmune hives explained: We explore how CSU can be autoimmune, why the immune system may attack itself, and what Type I and Type IIb autoimmune CSU really mean. ____ Made in partnership with The Allergy & Asthma Network. Thanks to Novartis for sponsoring today’s episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Indolent Systemic Mastocytosis (ISM) is a rare but often underrecognized clonal mast cell disorder. From random hives to gut pain and brain fog, ISM can feel like a medical mystery. We continue our review of “Management of indolent mastocytosis and mast cell activation syndrome - A clinical yardstick,” published in June 2025 in The Annals of Allergy, Asthma & Immunology. This is Part 2 of our discussion, with a focus on indolent systemic mastocytosis. We look at what causes it, how it’s diagnosed, and how to manage symptoms and improve quality of life. In this episode, we break down this complex mast cell disease and how doctors use baseline serum tryptase, KIT D816V testing, and HaT screening to find answers. Plus, we explain how treatments like antihistamines, mast cell stabilizers, and avapritinib can help people live better with ISM. 📌 INFOGRAPHIC to follow along What we cover in our episode about indolent systemic mastocytosis (ISM): Yardsticks explained: Why the ACAAI uses yardsticks as practical, interim guidelines before full consensus statements are available. Understanding mast cell diseases: The difference between primary (clonal), secondary (allergic), and idiopathic mast cell disorders. Diagnosing ISM: KIT D816V mutation, WHO/ICC criteria, baseline serum tryptase, and when to test for hereditary alpha-tryptasemia (HaT). Symptoms of ISM: Why symptoms vary and how they can involve multiple systems, including skin, GI tract, cardiovascular, and even neuropsychiatric. Management strategies: Trigger avoidance, antihistamines, leukotriene blockers, sodium cromolyn, aspirin therapy, and, when venom immunotherapy is appropriate. Targeted treatment: How avapritinib works and what the PIONEER study shows about its role in ISM. The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference. ___ Made in partnership with The Allergy & Asthma Network. Thanks to Blueprint Medicines for sponsoring today’s episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Mast cell activation syndrome (MCAS) is a confusing and often misunderstood condition. If you’ve ever wondered about MCAS symptoms, serum tryptase testing, or how treatments like antihistamines, sodium cromolyn, and even omalizumab fit in, this episode is here to help. We review the findings from “Management of indolent mastocytosis and mast cell activation syndrome - A clinical yardstick,” published in June 2025 in The Annals of Allergy, Asthma & Immunology. Because the paper covers both diseases, we’ve split it into two parts. This episode focuses on mast cell activation syndrome (MCAS). GET THE INFOGRAPHIC - summary of this episode What we cover in our episode about mast cell activation syndrome: Yardsticks explained: Why the ACAAI uses yardsticks as practical, interim guidelines before full consensus statements are available. Classifying mast cell disorders: Primary (clonal), secondary (allergy/autoimmune), and idiopathic (MCAS). MCAS diagnosis criteria: Symptoms in 2 or more organ systems, objective evidence (serum tryptase or urinary metabolites tests), and positive response to therapy. Treatment strategies: Include trigger avoidance, H1/H2 antihistamines, leukotriene blockers, mast cell stabilizers (such as cromolyn and aspirin), off-label biologics like omalizumab, and epinephrine. Neuropsychiatric symptoms: Brain fog, anxiety, and depression are common and require multidisciplinary management. The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference. Made in partnership with The Allergy & Asthma Network. Thanks to Blueprint Medicines for sponsoring today’s episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

As September approaches, many families notice asthma symptoms getting worse. Ragweed pollen, viral infections, cooler nights, and the stress of back-to-school routines all combine to create Asthma Peak Week, a time when asthma attacks and ER visits spike across the country. Asthma mom, Sherrina Gibson, joins us to share how her family prepares her 11-year-old daughter for fall asthma challenges. She talks about cleaning routines, school planning, and teaching her daughter self-awareness and empowerment. Dr. Payel Gupta adds medical guidance on asthma action plans and seasonal medication adjustments. You’ll learn how to spot asthma triggers, prepare your home and school, and teach children to recognize symptoms early so they can act before a flare gets worse. What we cover in our episode about preparing for asthma peak week: Parenting with asthma: Sherrina Gibson shares her family’s journey and how they prepare their home and routines each fall. Asthma management strategies: Cleaning, decluttering, updating medications, and coordinating with schools and coaches. Asthma Peak Week explained: Why symptoms spike in September and how to get ahead of it. Asthma action plans: Why every family needs one and how to keep copies at home, school, and on the go. Empowering kids with asthma: Teaching children to recognize symptoms, use their inhaler properly, and advocate for themselves at school and in sports. More episodes about asthma Ep. 81: Why asthma attacks rise in September peak week Ep. 58: What is controlled Asthma? - Everything you need to know! Ep. 117: As-Needed Albuterol–Budesonide in Mild Asthma (BATURA Trial) Ep. 124: Asthma peak week and understanding triggers Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca and Amgen for sponsoring today’s episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

As summer winds down and September approaches, many people with asthma notice their symptoms getting worse. This is no coincidence as more asthma triggers appear during this time of year, from pollen and viruses to stress and weather changes. This combination peaks during Asthma Peak Week, a time when asthma attacks and ER visits spike across the country. Allergist Dr. Kristin Sokol joins us to discuss seasonal asthma triggers, why fall can be especially risky, and how you can prepare to keep your asthma under control. You’ll learn how to identify your personal triggers, steps to reduce your exposure, and why staying consistent with your medication routine is critical. We also cover tools like an asthma action plan, preparing for school, and making sure caregivers and teachers know how to respond to an asthma flare. What we cover in our episode about managing asthma triggers during the fall: Understanding asthma: learn why even mild asthma should be reviewed before the fall. Identifying triggers: from indoor allergens to seasonal pollen and surprising emotional triggers, know what can set off your asthma. Preparing for Asthma Peak Week: discover how viruses, ragweed pollen, and stress combine into a dangerous flare period and how to get ahead of it. Staying in control: strategies to avoid or reduce asthma trigger exposure, prepare for school, and keep your asthma action plan up to date. Supporting everyone with asthma: special considerations for adults, caregivers, and teachers to stay healthy and ready year-round. More episodes about asthma Ep. 81: Why asthma attacks rise in September peak week Ep. 58: What is controlled Asthma? - Everything you need to know! Ep. 117: As-Needed Albuterol–Budesonide in Mild Asthma (BATURA Trial) Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca and Amgen for sponsoring today’s episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Parenting a child with food allergies can feel overwhelming and isolating. We're joined by licensed therapist and food allergy mom Tamara Hubbard, MA, LCPC, to talk about her new book, May Contain Anxiety, and the often overlooked mental health challenges that food allergy parents face. We explore how chronic stress, fear, and anxiety can affect parenting, relationships, and family dynamics. Plus, why supporting the mental health of allergy parents is crucial for the entire family’s well-being. Tamara breaks down evidence-based tools from Acceptance and Commitment Therapy (ACT) to help parents manage food allergy anxiety, build confidence, and feel less alone on this lifelong journey. What we cover in this episode about food allergy anxiety in parents: Tamara’s journey from substance abuse counselor to food allergy mental health advocate Why she wrote May Contain Anxiety and how it’s different from typical self-help books A breakdown of Acceptance and Commitment Therapy (ACT) and how it supports allergy parents The impact of food allergy anxiety on the whole family system, from parenting dynamics to sibling relationships Why this book is valuable for every stage of the allergy journey and helpful for allergists and extended family, too May Contain Anxiety is available worldwide in English on September 30th, 2025. Get 30% off by buying it at Hopkins Press and using the code: HMCA25

Do adults with chronic spontaneous urticaria (CSU) have a higher risk of death over time compared to people without hives? We review the findings from “Mortality in adult patients with chronic spontaneous urticaria: A real-world cohort study,” published in April 2025, in The Journal of Allergy and Clinical Immunology. While CSU is often considered a non-life-threatening condition, this large study found something surprising: people with CSU had a significantly higher risk of death, especially from suicide. Dr. G and Dr. Blaiss walk through key takeaways from a dataset of over 272,000 CSU patients and nearly 13 million matched controls. They explore what the results mean for mortality risk, clinical care, mental health screening, and the importance of proper, guideline-based treatment. What we cover in our episode about CSU and mortality risk: What is CSU? Chronic hives are an unpredictable, itchy, and sometimes painful condition. It lasts for 6 weeks or longer and can continue for years. Mental health connection: CSU affects more than skin. Anxiety, depression, and suicidal thoughts are common and serious concerns. Study findings: CSU was associated with higher mortality at 3 months, 1 year, and 5 years. Suicide risk was over 3 times higher than in people without CSU. Demographics: Younger and White patients with CSU had the highest increase in risk. Treatment impact: Patients using guideline-recommended treatments like second-generation antihistamines or omalizumab had lower death rates. INFOGRAPHIC The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference.   Made in partnership with The Allergy & Asthma Network. Thanks to Novartis for sponsoring today’s episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

What happens when you target the root cause of indolent systemic mastocytosis? In this episode of The Itch Review, we unpack key findings from the article “Avapritinib versus Placebo in Indolent Systemic Mastocytosis,” published on May 23, 2023, in NEJM Evidence. Indolent Systemic Mastocytosis (ISM) is a rare chronic disease with life-altering symptoms. Until recently, treatment options were limited. We break down new data from Part 2 of the PIONEER study, which evaluated Avapritinib, a targeted therapy designed to inhibit the KIT D816V mutation that drives ISM. Dr. Gupta and Dr. Blaiss explain how Avapritinib works, how the study was designed, and what outcomes were measured, including the Total Symptom Score (TSS). Most importantly, we explore what this treatment could mean for patients with moderate to severe ISM. INFOGRAPHIC What we cover in our episode about avapritinib versus placebo: Understanding ISM: How the KIT D816V mutation causes overproduction and overactivation of mast cells. Why current treatment falls short: The limitations of best supportive care and why many patients remain symptomatic despite multiple medications. How Avapritinib works: A tyrosine kinase inhibitor that targets the KIT mutation directly, aiming to reduce mast cell activation at its source. Inside the PIONEER trial: Study design, eligibility criteria, and how outcomes like Total Symptom Score (TSS) and serum tryptase were measured. What the data showed: Improvements in symptoms, lab markers, and quality of life and what this could mean for long-term ISM care. The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference.   Made in partnership with The Allergy & Asthma Network. Thanks to Blueprint Medicines for sponsoring today’s episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Is it too early to start planning for school when summer has just begun? Not if your child has food allergies. Dr. Nikki Chase, a board-certified allergist-immunologist, joins us to share what families need to know to prepare for a safe and successful school year. From school forms and emergency plans to when to self-carry epinephrine and how to teach self-advocacy, this episode is filled with practical, real-life guidance. We discuss how to make the most of your summer doctor visits, why early planning matters, and how newer epinephrine options, like the nasal spray, may help reduce fear and delay in use. You’ll also hear Dr. Chase’s advice on helping kids build confidence and take ownership of their allergy care. What we cover in our episode about preparing for school with food allergies:  504 plans explained: What they are, how to request one, and why they matter for legal protection and clear school accommodations. Anaphylaxis Action Plans: What’s included, how they differ from 504 plans, and why they take the guesswork out of emergencies. Epinephrine device options: From auto-injectors to nasal spray, what’s available and how to choose the best fit for your child. What to work on this summer to build allergy confidence: The rules, responsibilities, and privileges kids should practice to stay safe and feel more in control. Self-advocacy & communication tips: How to help your child speak up, navigate cafeteria dynamics, and respond to food allergy bullying. More resources about back-to-school with food allergies Planning for School with Food Allergies School Plans for Students with Food Allergies Managing Allergies in Schools: A Guide for Staff Epinephrine for Anaphylaxis: What Treatments are Available? Food Allergy Treatment & Management   Produced in partnership with The Allergy & Asthma Network. Thanks to ARS Pharma for sponsoring this episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Have you ever wondered what happens after an anaphylactic reaction? How do you process everything that went down, from ingesting the allergen to using epinephrine? In this candid conversation, Kortney sits down with Tamara Hubbard, a licensed clinical professional counselor, to unpack the emotional aftermath of a severe allergic reaction. Kortney shares her own recent experience of self-administering epinephrine for the first time after over 30 years of living with food allergies. Together, they explore how guilt, self-doubt, and family dynamics can shape recovery and how to move forward without letting fear or shame take over. What we cover in this episode about processing an anaphylactic reaction: The moment Kortney realized she needed to self-inject epinephrine and why it felt empowering. Why it’s common to second-guess yourself during an allergic reaction. The unique guilt and blame that can surface after a reaction, even when you did everything right. How to handle well-meaning but unhelpful comments from family and friends. Tips for processing the event without letting it define your future. About Our Guest Tamara Hubbard, MA, LCPC is a licensed clinical professional counselor and the founder of the Food Allergy Counselor Directory & Website. She specializes in helping individuals and families navigate the emotional and mental health challenges that come with managing food allergies. Tamara is passionate about empowering people to build confidence and resilience while living safely with food allergies. Learn more about Tamara’s work at FoodAllergyCounselor.com.

Do patients and their healthcare teams view the impact of indolent systemic mastocytosis on quality of life in the same way? In this episode of The Itch Review, we unpack key findings from a May 4, 2025, descriptive study from The Journal of the Advanced Practitioner in Oncology, “Patient and Advanced Practitioner Perspectives on Symptom Burden and Symptom Management in Indolent Systemic Mastocytosis.” Is there a disconnect between what patients feel and what providers think when it comes to indolent systemic mastocytosis (ISM)? A new study suggests yes, revealing a mismatch between how patients and advanced practitioners (APs) perceive disease control and what that means for care. This episode dives into whether research like this could help bridge the gap between patient experience and clinical perspective. What we cover in our episode about the indolent systemic mastocytosis: Understanding ISM: What makes indolent systemic mastocytosis a unique multisystem condition? Symptom burden explained: Frequency, severity, duration, distress, and functional interference. Patient vs practitioner views: Understanding the most impactful symptoms differs from patient to AP.  Practical tools: The Indolent Systemic Mastocytosis-Symptom Assessment Form (ISM-SAF) is a validated instrument that can be used to determine symptoms and severity. Barriers and solutions: Why tracking symptoms is hard and how clinics can improve coordination. AP-focused Toolkit: Resources to help nurse practitioners, PAs, and pharmacists provide patient-centered ISM care. GET THE INFOGRAPHIC HERE *** The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores the latest allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference. *** This podcast is made in partnership with The Allergy & Asthma Network. Thanks to Blueprint Medicines for sponsoring today’s episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

There have been countless advances in controller therapies for asthma, but our go-to rescue inhaler, a quick-relief bronchodilator, hasn’t changed in decades. In this episode of The Itch Review, we spotlight “As-Needed Albuterol–Budesonide in Mild Asthma” published in The New England Journal of Medicine, May 19, 2025. This article looks at the BATURA trial, which tested whether adding budesonide to albuterol rescue inhalers cuts exacerbations in adults whose mild asthma remains uncontrolled on occasional albuterol/short-acting beta agonist (SABA) therapy. Could this combo inhaler really cut severe asthma attacks in people with mild disease? What we cover in our episode about the BATURA trial: Understanding asthma: In asthma, your airways both tighten up and get swollen. Treating both the tightness and the swelling right when you feel symptoms could stop a full-blown attack. All-online trial: BATURA used telehealth to enroll 2,516 people with mild asthma from across the U.S. and ran the study until it saw a preset number of 172 serious attacks. Big takeaways: The combo inhaler cut serious attacks by almost half, halved yearly flare-ups, and slashed steroid use by 63%. All without people needing to use their medication more often. Why it ended early: An independent safety board reviewed the data mid-trial and concluded that the combo inhaler was so clearly better that it would’ve been unfair to continue giving anyone the old treatment. What’s next: We still need studies on teens and children to ensure that these same benefits hold true for younger patients. GET THE INFOGRAPHIC PDF HERE *** The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores the latest allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference. *** This podcast is made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today’s episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Have you ever wondered whether fexofenadine (Allegra®) really doesn’t make you drowsy? In this episode of The Itch Review, we dissect a July 2024 systematic review from Current Medical Research & Opinion, “Why fexofenadine is considered a truly non-sedating antihistamine with no brain penetration.”  This rigorous systematic review pools over 60 human studies from PET brain-scan trials and Proportional Impairment Ratio (PIR) tests to driving-simulator research and real-world quality-of-life surveys. It looks to answer one question: Does fexofendine ever sneak past the blood–brain barrier and slow you down like first-generation allergy meds? This episode looks at the evolution of H1 antihistamines from first-generation drugs like diphenhydramine to today’s second-generation options (cetirizine, loratadine, and fexofenadine) to show how each interacts with the blood–brain barrier (BBB) and why that matters for sedation. We highlight the review’s key studies: PET Imaging: Measuring H1-receptor occupancy. Fexofenadine registers <1%, even at high doses PIR Analyses: Proportional Impairment Ratio tests show virtually zero cognitive or motor impairment when taking fexofenadine Driving & Aviator Trials: Side-by-side comparisons with diphenhydramine, alcohol, and fexofenadine Finally, we dive into real-world outcomes on reaction times, work-and-school performance, pediatric safety, and even NASA’s approval for pilot use. GET THE INFOGRAPHIC TO FOLLOW ALONG *** The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores the latest allergy and immunology studies through 30-minute conversations that are accessible for everyone. This podcast aims to support busy clinicians, patients, and caregivers in staying updated on current research. Each episode provides valuable insights from key journal articles and includes a convenient one-page infographic in the show notes for easy reference. *** This podcast is made in partnership with The Allergy & Asthma Network. Thanks to Opella for sponsoring today’s episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Stepping into young adulthood also means stepping up as the primary manager of your food allergies. For teens and young adults with food allergies, early adulthood is an exciting but challenging shift. It’s the first time you’re the primary communicator, managing everything from dining halls to doctor’s appointments on your own. Add in new living spaces, new friends, and a growing social life, and there’s a lot to navigate. Dr. Theresa Bingemann joins Kortney and Dr. Payel Gupta to unpack how food allergy management changes as you step into early adulthood. We cover self-advocacy skills, emergency preparedness, how to create allergy-friendly spaces in shared housing, and tips for navigating social life safely. Plus, we dive into practical advice for managing stress, staying emotionally healthy, and finding your footing in this new phase of life. What we cover in our episode about managing food allergies in young adults: Self-advocacy matters. Learn how to speak up about your allergies with confidence. Planning ahead for emergencies. Practicing with an epinephrine device is not just for kids! Plus, knowing the available campus resources is key to feeling secure in your food allergy management. Creating a safe living space. Tips for setting up allergy-friendly dorm rooms and kitchens with roommates. Navigating social life. How to handle parties, dating, and dining out while staying safe. Managing emotional well-being. Support strategies for handling anxiety, stress, and the transition to independence. Episode 6 in our “Food Allergies: Ages & Stages” series  Across six episodes, we explore how food allergies show up and shift through different phases of life, from introducing solids in infancy to navigating school and adapting in adulthood. We’re here with evidence-based info, expert insights, and lived experience to guide you through it all. Episode 110: Early Allergen Introduction Episode 111: Food Allergy Basics for Newly Diagnosed Families Episode 112: Managing Food Allergies in Babies and Toddlers Episode 113: Managing Food Allergies in School-Age Children Episode 114: Managing Food Allergies in Teens AAAAI Ages & Stages PDFs Food Allergy Stages: Young Adults (18–21 years) Thanks to Genentech and Aquestive for sponsoring this episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.